Last reviewed · How we verify

NaPBA — Competitive Intelligence Brief

NaPBA (NaPBA) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Ammonia scavenger. Area: Metabolic/Genetic Disorders.

marketed Ammonia scavenger Metabolic/Genetic Disorders Small molecule Live · refreshed every 30 min

Target snapshot

NaPBA (NaPBA) — Amgen. NaPBA (sodium phenylbutyrate) reduces ammonia levels by providing an alternative pathway for nitrogen excretion through conjugation with glutamine.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
NaPBA TARGET NaPBA Amgen marketed Ammonia scavenger

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Ammonia scavenger class)

  1. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NaPBA — Competitive Intelligence Brief. https://druglandscape.com/ci/napba. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: